You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Lead Compound Discovery from Engineered Analogs of Occidiofungin
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
SBC: CBS THERAPEUTICS, INC. Topic: 102ABSTRACT Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide H S in colorectal cancer In specific the selective upregulation of cystathionine synthase CBS and the subsequent production of H S in colonic cancer cells serves as a pro survival factor by stimulating tumor cell bioenergetics ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Microparticulate mucosal vaccine for triple-negative breast cancer
SBC: KIROMIC BIOPHARMA INC Topic: 103ABSTRACT Triple negative breast cancerTNBCis a molecular subtype of breast cancer that is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptorHERClinicallyit is characterized by aggressive behaviordistinct patterns of metastasisand high rates of recurrence and mortalitySince TNBC tumor cells lack the necessary receptorsthe disease does not respo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Targeting Synaptotagmin to Prevent Airway Mucus Obstruction
SBC: Exotect, LLC Topic: NHLBIPROJECT SUMMARY Mucus dysfunction underlies the pathophysiology of a number of common respiratory diseases including asthma cystic fibrosis and chronic obstructive pulmonary disease COPD Asthma alone impacts of the US population resulting in considerable cost morbidity and occasional mortality caused by mucus hypersecretion Recently it was discovered that Synaptotagmin Syt regul ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Investigation of antibody drug conjugates of a novel target
SBC: WNTRIX INC Topic: NCIPROJECT SUMMARY Antibody drug conjugates ADCs are monoclonal antibodies mAbs that are covalently linked to cell killing drugs and have emerged as a major modality in anti cancer treatment This approach combines high specificity of mAbs against their antigen targets with highly potent cytotoxic drugs resulting in armed mAbs that deliver the payload drug to tumor cells with enriched levels ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Cloud based Application for the Joint Analysis of Multiple Big Data Types
SBC: MathNimbus Inc Topic: 400Project Summary Technology advances now enable the cost effective acquisition of Kandgt distinct data types from a common set of N bio samples where i the kth data type is represented by a data matrix with columns containing Pk measurements in N samples for k K and ii at least one of the data types is big i e Pk is much bigger than N for some k The rapid accumulation of such mult ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Raising the Therapeutic Index of Photodynamic Therapy with Targeted Nanosyringes
SBC: NANOHYBRIDS INC Topic: 102ABSTRACT Current clinical photodynamic therapy PDT is an effective cancer treatment that is non invasive and low cost but it has yet to become a mainstream frontline treatment The clinical efficacy of PDT in solid tumors depends on significant accumulation of the photosensitizer PS at the tumor site availability of oxygen near the photosensitizer and effective dosing of the drug light c ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing an automated yeast dissection system for aging research
SBC: Innovative BioChips LLC Topic: NIAProject Summary Developing an Automated Yeast Dissection System for Aging Research Aging is the single greatest risk factor for diseases that are principal causes of mortality The objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseases The budding yeast Sacchar ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial Targeted Nano antioxidants to Treat Alzheimer s Disease
SBC: Acelerox, LLC Topic: NIAABSTRACT PROJECT SUMMARY Alzheimer s disease AD is characterized by hyperphosphorylated tau protein which causes impaired axonal transport in neurons In recent years multiple researchers have determined that oxidative stress appears to be a significant early event in the pathogenesis of AD in preclinical AD models and in AD patients We have shown that reducing oxidative stress through quench ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration
SBC: EscaZyme Biochemicals, LLC Topic: NProject Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health